Many fitness users stack AOD 9604 with Frag 176-191 or a GLP-1 agonist for enhanced lipolysis
What the Research Found The research, published in the Annals of Internal Medicine , examined whether people with type 2 diabetes taking GLP-1 receptor agonists such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) face a higher risk of ischaemic optic neuropathy
GeroScience 45 (4), 236786
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
The co-primary endpoints were the percentage change of weight reduction in the Tirzepatide 10mg and 15mg dose groups at week 72 and the percentage of participants achieving 5% body weight reduction at 72 weeks compared to placebo
Does Diet Coke Make You Retain Water
